2026-08-03
An FDA advisory panel voted in late July to allow compounding pharmacies to produce six of seven unapproved peptide injectables, including BPC-157, TB-500, and MOTS-c, but the vote does not itself change the legal status of the substances. The agency must now weigh safety and efficacy evidence and decide whether to formally permit compounding, a process that could take months or be accelerated through an unusual regulatory maneuver.
2026-07-23
A Food and Drug Administration advisory committee began a two-day meeting Thursday to weigh whether to allow compounding pharmacies to produce seven unapproved peptide injections, including the injury-recovery compounds BPC-157 and TB-500. The meeting has the backing of Health Secretary Robert F. Kennedy Jr., who has described himself as a "big fan" of peptides and has vowed to overturn industry restrictions imposed under former President Joe Biden.
2026-07-08
An FDA advisory committee will meet July 23-24 to consider whether to allow compounding pharmacies to manufacture seven unapproved peptide therapies, including the injury-recovery compound BPC-157 and the muscle-repair drug TB-500. The meeting comes after Health Secretary Robert F. Kennedy Jr. vowed to overturn Biden-era restrictions on the substances, which have fueled a gray market supplied by overseas vendors.